1. Peer Review for Paediatric Diabetes Ruth Bridgeman

2. The New Health Environment

3. Benefits of Peer Review Provision of disease specific information across the country together with information about individual teams which has been externally validated Provision of benchmark data Provision of a catalyst for change and service improvement Identification and resolution of immediate risks to patients and or staff Engagement of a substantial number of front line clinicians in reviews

4. Benefits of Peer Review Clinical support for a peer review Enabled rapid sharing of learning between clinicians, as well as a better understanding of : –Commissioning Services for Children and Young People with Diabetes –Delivering the Diabetes National Service Framework

5. Measures Methodology – Developed by a small expert group –Fiona Campbell / Philip Holland –Ian Manifold, Ruth Bridgeman and James Heasman Developmental –Unlikely to achieve 100% in the first round of review –Opportunity to test with the pilot –Looking to share good practice Organisational Approach –Network Level –Hospital Level –MDT Level

6. Measures D11-1A-100– CYPDN MEASURES Measure Number D11-1A-101 Chair of the CYPDN D11-1A-102 Membership and terms of reference of the CYPDN D11-1A-103 CYPDN Meetings D11-1A-104 CYPDN Annual Report D11-1A-105 CYPDN proposals for service development D11-1A-106 The Configuration of MDTs within the CYPDN D11-1A-107 Clinical Guidelines D11-1A-108 Agreed Network wide diabetes minimum dataset (MDS) D11-1A-109 Children and Young People Diabetes Network review of progress against diabetes audit D11-1A-110 Twenty-four hour telephone service specification

7. Measures D11-1D-100–HOSPITAL MEASURES FOR CHILDREN AND YOUNG PEOPLE DIABETES SERVICES Measure Number D11-1D-101 Children and Young People diabetes service specification for patient access D11-1D-102 Minimum consultation period D11-1D-103 Availability of information in an Outpatient environment D11-1D-104 Availability of ICU/HDU D11-1D-105 Review of Children and Young People admissions on a quarterly basis

8. Measures D11-2A-100–CHILDREN AND YOUNG PEOPLE DIABETES MDT MEASURES Measure Number D11-2A-101 Lead Clinician and Responsibilities D11-2A-102 CYPDN Attendance D11-2A-103 CYPD MDT Core Team Membership D11-2A-104 Extended team membership D11-2A-105 Policy for patients to be discussed by the CYPD MDT D11-2A-106 Treatment planning meeting D11-2A-107 Cover arrangements for core members D11-2A-108 Operational policy meeting D11-2A-109 Informing the GP of the diagnosis and initial prescribing D11-2A-110 Key worker policy D11-2A-111 Specialist training for core nurse member D11-2A-112 List of responsibilities for core nurse members D11-2A-113 Access to core CYPD MDT members for follow-up patients D11-2A-114 Patients’ permanent consultation record D11-2A-115 Patients’ experience exercise D11-2A-116 Outcome of patients’ experience exercise D11-2A-117 Provision of patient written information D11-2A-118 Clinical guidelines D11-2A-119 Policy for the management of patients whose HBA1c rating is greater than 9.5. D11-2A-120 Policy for the screening of children and young people with type 1 diabetes D11-2A-121 Policy for patient choice of insulin pump therapy D11-2A-122 Teaching of the principles of carbohydrate counting D11-2A-123 Training policy for new patients D11-2A-124 Management transfer of young people to young adults clinic D11-2A-125 Data collection D11-2A-126 Participation in audit D11-2A-127 Presentation and review of audit activity

9. Handbook This is the key document Explains the processes to be used for the pilot

10. Visit Programme Agree Pilot Visits –Network Visit –Calderdale –Bradford –Hull Agree Dates –28 March – Hull –29 March – Calderdale –30 March – Bradford –Network Visit to be confirmed

11. Visit Programme Letter’s to confirm visit to go the CEOs Self Assessment deadlines 18 March 2011 Pre visits 1 st 2 nd 3nd March – if requested Visits –28 March – Hull –29 March – Calderdale –30 March – Bradford –Network Visit to be confirmed

12. Evaluation of the pilot Programme Report by the Quality Manager –Details of the outcomes of the pilot –Evaluation of the pilot –Recommended next steps